Company intelligence / Profile preview

Rize Oncology Inc.

Kelowna, British Columbia, Canadarizeoncology.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Rize Oncology is developing STS-201, a small molecule drug candidate for the treatment of soft tissue sarcoma. The drug has shown significant utility in soft tissue sarcoma and other cancer types. STS-201's mechanism of action includes blocking cell division at the late G2/M boundary, slowing tumor proliferation, increasing oxygen in the tumor microenvironment, and forming more complete tumor vasculature to reduce metastasis.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

STS-201

Preclinical

Beyond the preview

Go deeper on Rize Oncology Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rize Oncology Inc..

Explore the full profile